The global Giant Cell Arteritis (GCA) treatment market was valued at approximately USD 1.19 billion in 2025 and is projected to expand to USD 2.08 billion by 2032, exhibiting a CAGR of 6.4 %. Another analysis forecasts a rise from USD 1.07 billion in 2024 to USD 1.30 billion by 2028, growing at about 5.1 % CAGR. This steady growth is primarily driven by increased GCA prevalence in aging demographics, greater biomarker-based diagnosis, and expanding reimbursement for corticosteroids and biologics.

Get CI Consultation: https://www.datamintelligence.com/strategic-insights/ci/giant-cell-arteritis-gca

Key Market Drivers & Growth Opportunities
GCA therapy is being reshaped by multiple factors. Aging populations and the rising incidence of large-vessel vasculitis have increased demand. Growing awareness among rheumatologists and GPs contributes to earlier and more accurate diagnosis. Importantly, novel therapies such as Upadacitinib (RINVOQ) approved in early 2025 and Secukinumab (COSENTYX), currently in Phase III GCAptAIN trials by Novartis, offer alternatives to corticosteroids. Biosimilars like Tocilizumab-aazg (FDA-approved April 2024) add cost-effective options.

Target Markets: Adoption in the US and Japan
The United States dominates the GCA market, accounting for around 54% of cases in 2023, with robust uptake of tocilizumab and the arrival of oral Upadacitinib enhancing treatment flexibility. In Japan, an aging population and coordinated care systems drive demand. While biologics penetration grows, clinical trials for Secukinumab and mavrilimumab support future expansions.

Approved Therapies & Pipeline
* Tocilizumab (Actemra/RoActemra) remains the only approved biologic since 2017; biosimilar Tocilizumab‑aazg launched in April 2024.
* Upadacitinib (RINVOQ) gained FDA approval in April 2025 for GCA, offering an oral JAK1 inhibitor option and positioning itself as the market leader by 2034.
* Secukinumab (COSENTYX) is in late-stage Phase III GCAptAIN trials, building on positive Phase II data with steroid-sparing benefit.
* Other noteworthy candidates: Guselkumab (TREMFYA) and Mavrilimumab are making headway in mid-/late-stage studies.

Key Players: Leading the Innovation Charge
Key industry players navigating the GCA landscape include:
* Roche / Chugai – Pioneers with Actemra; launching biosimilars.
* AbbVie – RINVOQ’s FDA approval marks leadership in oral therapy.
* Novartis – Advancing Secukinumab as a late-stage steroid-sparing agent.
* J&J / MorphoSys – Exploring guselkumab in late-stage trials.
* CSL / Kiniksa – Developing mavrilimumab to expand therapeutic options.
* Fresenius – Marketed tocilizumab‑aazg biosimilar in April 2024.

Diagnostic innovators are also contributing, with biomarker-based imaging and advanced molecular testing evolving standard care.

Read the full CI Insights report: https://www.datamintelligence.com/strategic-insights/giant-cell-arteritis-gca

Market Outlook: Precision Therapies Define the Next Decade
The future of GCA treatment hinges on:
* Personalized therapies: Mechanism-driven drugs (e.g., IL‑6, IL‑17, JAK1, GM-CSF) allow tailored care.
* Steroid reduction: New agents offer safer, longer-term alternatives.
* Expanded biosimilars: Cost-effective options improve access and compliance.
* Diagnostics: AI-based imaging and molecular biomarkers will enhance early detection and response monitoring.
* Geographic expansion: Emerging markets will embrace newer therapies, contingent on reimbursement frameworks.

About Us

DataM Intelligence 4Market Research LLP provides Competitive Intelligence services, delivering insights on pipelines, clinical developments, regulatory updates, KOL analytics, and market strategies in life sciences.

Contact Us

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: [email protected]

Phone: +1 877 441 4866
Website: https://www.datamintelligence.com